PepGen (PEPG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, to be held virtually for stockholders of record as of April 21, 2026.
Stockholders are encouraged to review proxy materials online or request paper copies by June 8, 2026.
Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 annual meeting or until earlier departure.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting FOR both proposals.
Any other business may be transacted at the meeting at the discretion of the proxies.
Board of directors and corporate governance
Nominees for Class I director positions are Howard Mayer, Joshua Resnick, and Lisa Wyman.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PepGen
- Net loss narrowed as R&D spending declined; cash runway extends into Q4 2027.PEPG
Q2 2026 - PGN-EDODM1 delivers robust splicing correction and favorable safety in DM1 trials.PEPG
Company presentation - DM1 trials achieved record splicing gains and strong safety, with pivotal data due Q1 next year.PEPG
Stifel 2025 Healthcare Conference - Biotech seeks up to $400M in flexible offerings, including $100M ATM sales, to fund R&D and operations.PEPG
Registration filing - PGN-EDODM1 delivers strong splicing correction and safety in DM1, with pivotal data ahead.PEPG
Company presentation - Executive agreements updated and FREEDOM2 trial advanced, with cash runway into 2H 2027.PEPG
Q1 2026 - Stockholders will vote on director elections and auditor ratification at a virtual annual meeting.PEPG
Proxy filing - PGN-EDODM1 shows strong efficacy and safety in DM1, with pivotal data expected by 2027.PEPG
Company presentation - PGN-EDODM1 at 5 mg/kg showed strong safety and splicing correction, supporting dose escalation.PEPG
Study update